NCT03766763 2025-11-26
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
Clinical Trials
22 trialsNCT06812715 2025-08-06
PIPOZA
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT04515238 2025-06-10
CLL2-BZAG
German CLL Study Group
Phase 2 Active not recruiting
NCT04883749 2025-06-08
CLL-Frail
German CLL Study Group
Phase 2 Completed
NCT03787264 2024-12-30
CLL2-BAAG
German CLL Study Group
Phase 2 Completed
NCT04605666 2024-08-20
CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 2 Completed
NCT01597219 2024-05-03
UK-Haplo
University College, London
Phase 2 Completed
NCT05082519 2023-10-26
IDEAL2
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Recruiting
NCT03899337 2023-01-09
STELLAR
University of Birmingham
Phase 2 Recruiting
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting
NCT03068416 2021-10-20
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Uppsala University
Phase 2 Completed
NCT02689141 2020-06-11
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
German CLL Study Group
Phase 2 Completed
NCT03598179 2019-08-07
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01279252 2019-01-25
CLEAR
King's College Hospital NHS Trust
Phase 2 Completed
NCT01446900 2018-01-31
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
European Institute of Oncology
Phase 2 Terminated
NCT00201721 2017-02-08
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00751296 2016-06-16
Rev-CLL
University Health Network, Toronto
Phase 2 Terminated
NCT00230282 2014-10-06
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
Stanford University
Phase 2 Completed
NCT01127542 2011-12-05
RESPeCT
The Christie NHS Foundation Trust
Phase 2 Terminated
NCT00558181 2010-02-23
LT-CLL-001
Vilnius University
Phase 2 Completed
NCT00292760 2009-12-16
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
Royal Marsden NHS Foundation Trust
Phase 2 Completed